Trending

#PTCy

Latest posts tagged with #PTCy on Bluesky

Latest Top
Trending

Posts tagged #PTCy

Fig 1. Association of donor age with OS. (A) The plot shows the unadjusted HR for death according to donor age. A linear model (red line) is compared with a more flexible spline model (blue line), which allows for a non-linear relationship. Shaded ribbons represent 95% CIs. The similarity between the two models and the fact that their CIs consistently overlap an HR of 1.0 indicates that there is no significant linear or nonlinear association between donor age and survival in this cohort. (B) Kaplan-Meier analysis of OS stratified by dichotomized donor age: donors younger than 32 years (red) versus those 32 years and older (blue). There was no statistically significant difference in survival between the two groups (log-rank P = .51). HR, hazard ratio; OS, overall survival.

Fig 1. Association of donor age with OS. (A) The plot shows the unadjusted HR for death according to donor age. A linear model (red line) is compared with a more flexible spline model (blue line), which allows for a non-linear relationship. Shaded ribbons represent 95% CIs. The similarity between the two models and the fact that their CIs consistently overlap an HR of 1.0 indicates that there is no significant linear or nonlinear association between donor age and survival in this cohort. (B) Kaplan-Meier analysis of OS stratified by dichotomized donor age: donors younger than 32 years (red) versus those 32 years and older (blue). There was no statistically significant difference in survival between the two groups (log-rank P = .51). HR, hazard ratio; OS, overall survival.

How important is #HCT donor age in the #PTCy era? Large single-center study in JCO OP raises the question of how strongly age should be prioritized:

ascopubs.org/doi/10.1200/... @EJShpallMD

2 0 0 0
Preview
Nico Gagelmann: Closing the Gap - PTCy Boosts Survival After Mismatched Stem Cell Transplants - OncoDaily Nico Gagelmann: Closing the Gap - PTCy Boosts Survival After Mismatched Stem Cell Transplants / Abeer Madbouly, Alison Loren, Antonio Martin Jimenez Jimenez,

Closing the Gap: PTCy Boosts Survival After Mismatched Stem Cell Transplants - Nico Gagelmann
@nicogagelmann.bsky.social

oncodaily.com/insight/nico...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PTCy #StemCellTransplants

6 0 0 0

The #NIH supported post-transplantation cyclophosphamide #PtCY for GVHD prophylaxis. It has changed the landscape of #HSCT.
And ensured my successful haplo #BMT for B&Tcell ALL.
@josemeade.bsky.social

1 0 0 0
Preview
Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study PTCY 50 mg/kg/day on days +3/+4 is an excellent strategy to prevent GVHD. However, its use is associated with adverse outcomes such as delayed engraftment, increased risk of infection, and cardiac com...

Can we reduce #PTCy dose and ditch #MMF altogether in matched donor allotransplantation? Interesting data from Spain: www.mdpi.com/2072-6694/16...

3 0 0 0

Love seeing the new pubs for #PTCy. Amazing strategy for #GVHD prophylaxis. The Stem Cell Lab team and I talked about the ⬆️ haplos and the OS in graft function across the board in the past 5 years. And the numbers are reflecting how well patients are doing in the long term. Great work! 🎉

3 1 0 0
Preview
Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202 Key PointsPTCy uniquely alters vascular biomarkers, with an increase in Ang-2 and a decrease in EGF at day +28 after transplant.Tac/Sir regimen also alters

#PTCy increases Ang2 and decreases EGF. Possible relationship to toxicity profile? ashpublications.org/bloodvth/art...

2 0 0 0
Post image

Alternatives to #PTCy @MGooptu Lower rates of steroid-requiring chronic #GVHD with Tac/Mtx/Obinutuzumab. 1/3 developed neutropenia.

2 1 1 0
Post image

Here we go! @BrianShafferMD leading us through the morning session addressing controversies re: #PTCy. Dose? Alternatives? Toxicities? @ASTCT #ToxicitiesConference24

2 0 2 0